119 related articles for article (PubMed ID: 38266312)
1. ANP32B inhibition suppresses the growth of prostate cancer cells by regulating c-Myc signaling.
Zhou C; Ma H; Yu W; Zhou Y; Zhang X; Meng Y; Chen C; Zhang J; Shi G
Biochem Biophys Res Commun; 2024 Feb; 698():149543. PubMed ID: 38266312
[TBL] [Abstract][Full Text] [Related]
2. SPOP regulates prostate epithelial cell proliferation and promotes ubiquitination and turnover of c-MYC oncoprotein.
Geng C; Kaochar S; Li M; Rajapakshe K; Fiskus W; Dong J; Foley C; Dong B; Zhang L; Kwon OJ; Shah SS; Bolaki M; Xin L; Ittmann M; O'Malley BW; Coarfa C; Mitsiades N
Oncogene; 2017 Aug; 36(33):4767-4777. PubMed ID: 28414305
[TBL] [Abstract][Full Text] [Related]
3. Targeting SMYD2 inhibits prostate cancer cell growth by regulating c-Myc signaling.
Li J; Wan F; Zhang J; Zheng S; Yang Y; Hong Z; Dai B
Mol Carcinog; 2023 Jul; 62(7):940-950. PubMed ID: 37036190
[TBL] [Abstract][Full Text] [Related]
4. Molecular landscape of c-Myc signaling in prostate cancer: A roadmap to clinical translation.
Faskhoudi MA; Molaei P; Sadrkhanloo M; Orouei S; Hashemi M; Bokaie S; Rashidi M; Entezari M; Zarrabi A; Hushmandi K; Mirzaei S; Gholami MH
Pathol Res Pract; 2022 May; 233():153851. PubMed ID: 35339914
[TBL] [Abstract][Full Text] [Related]
5. ANP32B deficiency impairs proliferation and suppresses tumor progression by regulating AKT phosphorylation.
Yang S; Zhou L; Reilly PT; Shen SM; He P; Zhu XN; Li CX; Wang LS; Mak TW; Chen GQ; Yu Y
Cell Death Dis; 2016 Feb; 7(2):e2082. PubMed ID: 26844697
[TBL] [Abstract][Full Text] [Related]
6. Troglitazone suppresses c-Myc levels in human prostate cancer cells via a PPARĪ³-independent mechanism.
Akinyeke TO; Stewart LV
Cancer Biol Ther; 2011 Jun; 11(12):1046-58. PubMed ID: 21525782
[TBL] [Abstract][Full Text] [Related]
7.
Umbreen S; Banday MM; Jamroze A; Mansini AP; Ganaie AA; Ferrari MG; Maqbool R; Beigh FH; Murugan P; Morrissey C; Corey E; Konety BR; Saleem M
Mol Cancer Ther; 2019 Nov; 18(11):2111-2123. PubMed ID: 31467179
[TBL] [Abstract][Full Text] [Related]
8. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Fan L; Peng G; Sahgal N; Fazli L; Gleave M; Zhang Y; Hussain A; Qi J
Oncogene; 2016 May; 35(19):2441-52. PubMed ID: 26279298
[TBL] [Abstract][Full Text] [Related]
9. Wedelolactone, an Anti-inflammatory Botanical, Interrupts c-Myc Oncogenic Signaling and Synergizes with Enzalutamide to Induce Apoptosis in Prostate Cancer Cells.
Sarveswaran S; Ghosh R; Parikh R; Ghosh J
Mol Cancer Ther; 2016 Nov; 15(11):2791-2801. PubMed ID: 27474149
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of BRD4 suppresses tumor growth in prostate cancer via the enhancement of FOXO1 expression.
Tan Y; Wang L; Du Y; Liu X; Chen Z; Weng X; Guo J; Chen H; Wang M; Wang X
Int J Oncol; 2018 Dec; 53(6):2503-2517. PubMed ID: 30272279
[TBL] [Abstract][Full Text] [Related]
11. Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity.
Kim J; Roh M; Abdulkadir SA
BMC Cancer; 2010 Jun; 10():248. PubMed ID: 20515470
[TBL] [Abstract][Full Text] [Related]
12. Transcription factor FoxM1 is the downstream target of c-Myc and contributes to the development of prostate cancer.
Pan H; Zhu Y; Wei W; Shao S; Rui X
World J Surg Oncol; 2018 Mar; 16(1):59. PubMed ID: 29554906
[TBL] [Abstract][Full Text] [Related]
13. O-GlcNAc transferase integrates metabolic pathways to regulate the stability of c-MYC in human prostate cancer cells.
Itkonen HM; Minner S; Guldvik IJ; Sandmann MJ; Tsourlakis MC; Berge V; Svindland A; Schlomm T; Mills IG
Cancer Res; 2013 Aug; 73(16):5277-87. PubMed ID: 23720054
[TBL] [Abstract][Full Text] [Related]
14. Guttiferone K impedes cell cycle re-entry of quiescent prostate cancer cells via stabilization of FBXW7 and subsequent c-MYC degradation.
Xi Z; Yao M; Li Y; Xie C; Holst J; Liu T; Cai S; Lao Y; Tan H; Xu HX; Dong Q
Cell Death Dis; 2016 Jun; 7(6):e2252. PubMed ID: 27253416
[TBL] [Abstract][Full Text] [Related]
15. Super enhancer related gene ANP32B promotes the proliferation of acute myeloid leukemia by enhancing MYC through histone acetylation.
Wan X; Wang J; Fang F; Hu Y; Zhang Z; Tao Y; Zhang Y; Yu J; Wu Y; Zhou B; Yin H; Ma L; Li X; Zhuo R; Cheng W; Zhang S; Pan J; Lu J; Hu S
Cancer Cell Int; 2024 Feb; 24(1):81. PubMed ID: 38383388
[TBL] [Abstract][Full Text] [Related]
16. CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.
Zhang C; Gao C; Xu Y; Zhang Z
Gene; 2014 Aug; 546(1):73-9. PubMed ID: 24835310
[TBL] [Abstract][Full Text] [Related]
17. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
18. Increased Akt signaling resulting from the loss of androgen responsiveness in prostate cancer.
Dulinska-Litewka J; McCubrey JA; Laidler P
Curr Med Chem; 2013; 20(1):144-57. PubMed ID: 23033951
[TBL] [Abstract][Full Text] [Related]
19. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
[TBL] [Abstract][Full Text] [Related]
20. NCAPG2 promotes prostate cancer malignancy and stemness via STAT3/c-MYC signaling.
Zhang E; Chen Z; Liu W; Lin L; Wu L; Guan J; Wang J; Kong C; Bi J; Zhang M
J Transl Med; 2024 Jan; 22(1):12. PubMed ID: 38166947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
